---
phase: 3
status: PASS
tasks_total: 3
tasks_passed: 3
tasks_failed: 0
---

# Phase 3 Result: Gate A Validation

## Per-Task Status

| Task ID | Title | Tier | Status | Evidence |
|---------|-------|------|--------|----------|
| T03.01 | Assemble Gate A Evidence Pack | STRICT | pass | `artifacts/D-0016/evidence.md`, `artifacts/D-0016/notes.md` |
| T03.02 | Issue Phase 3 Sign-Off Decision (Go/No-Go) | STANDARD | pass | `artifacts/D-0017/spec.md` |
| T03.03 | Document Phase 1-2 Defect Log | STANDARD | pass | `artifacts/D-0018/evidence.md` |

## Gate A Decision

**GO** -- Phase 4 is authorized to proceed.

### Gate A Exit Conditions

| Condition | Status | Evidence |
|-----------|--------|----------|
| v0.04 findings present (AC-1, AC-2) | PASS | D-0008 via D-0016 Section 1 |
| Overhead within budget (<25% SC-004) | PASS | ~15.3% mid-estimate via D-0016 Section 2 |
| All Phase 1-2 artifacts complete | PASS | 15/15 deliverables via D-0016 Section 3 |

## Files Modified

- `artifacts/D-0016/evidence.md` -- Gate A evidence pack (NEW)
- `artifacts/D-0016/notes.md` -- Evidence pack assembly notes (NEW)
- `artifacts/D-0017/spec.md` -- Go/no-go decision record (NEW)
- `artifacts/D-0018/evidence.md` -- Phase 1-2 defect log (NEW)
- `checkpoints/CP-P03-END.md` -- End of Phase 3 checkpoint (NEW)

## Deliverables Produced

| Deliverable | Path | Status |
|-------------|------|--------|
| D-0016 | `artifacts/D-0016/evidence.md` | Complete |
| D-0017 | `artifacts/D-0017/spec.md` | Complete |
| D-0018 | `artifacts/D-0018/evidence.md` | Complete |

## Defects Found

| Defect ID | Severity | Description | Status |
|-----------|----------|-------------|--------|
| DEF-001 | LOW | v0.04 spec not found as standalone file | ACCEPTED (representative specs used) |
| DEF-002 | MEDIUM | NFR-4 boundary table overhead marginal (mid: 10.3%) | ACCEPTED (within SC-004 <25% cumulative) |

## Blockers for Next Phase

None. Gate A decision is GO. Phase 4 may proceed.

**Recommendations for Phase 4:**
1. Monitor NFR-4 overhead with actual end-to-end panel runs
2. Use consistent representative-specification methodology for validation
3. No specification changes required before Phase 4 entry

EXIT_RECOMMENDATION: CONTINUE
